Please try another search
For the fiscal year ended 31 December 2018, Clementia Pharmaceuticals Inc revenues was not reported. Net loss decreased 50% to $58.1M. Lower net loss reflects Loss on re-measurement at fair value decrease from $77.9M (expense) to $0K, Accretion—preferred shares decrease from $2.5M (expense) to $0K, Interest income increase from $1.1M to $2.4M (income). Basic Earnings per Share excluding Extraordinary Items increased from -$7.93 to -$1.78.
Period Ending: | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -19.75 | -14.78 | -11.13 | -13.7 |
Net Income | -19.35 | -14.78 | -10.77 | -13.23 |
Period Ending: | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 |
---|---|---|---|---|
Total Assets | 176.84 | 115.38 | 128.17 | 137.87 |
Total Liabilities | 12.41 | 8.79 | 8.46 | 8.66 |
Total Equity | 164.43 | 106.59 | 119.71 | 129.21 |
Period Ending: | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 |
---|---|---|---|---|
Period Length: | 12 Months | 9 Months | 6 Months | 3 Months |
Cash From Operating Activities | -49.14 | -36.15 | -23.49 | -9.74 |
Cash From Investing Activities | 32.23 | 12.02 | 0.26 | 0.17 |
Cash From Financing Activities | 75.78 | 0 | 0 | 0 |
Net Change in Cash | 58.74 | -24.17 | -23.29 | -9.59 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review